Checkmate Pharmaceuticals Inc 's ROA from the first quarter of 2022 to the first quarter of 2021 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Checkmate Pharmaceuticals Inc 's ROA in the first quarter of 2022?
Checkmate Pharmaceuticals Inc recorded a cumulative net loss of $-63 million during 12 months ending in the first quarter of 2022, resulting in a negative return on assets (ROA) of -75.01%.

However, within the Healthcare sector 953 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2022 quarter, so far to 5234, from total ROA ranking in the fourth quarter of 2021 at 5496.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2022) I. Quarter	(Dec 31 2021) IV. Quarter	(Sep 30 2021) III. Quarter	(Jun 30 2021) II. Quarter	(Mar 31 2021) I. Quarter
Y / Y Total Assets Change	-44.16 %	-70.77 %	-37.99 %	21.84 %	2235.29 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-63	-61	-59	-54	-44
Return On Assets (TTM)	-75.01 %	-63.05 %	-40.65 %	-33.92 %	-28.31 %
CMPI's Total Ranking	# 5234	# 5496	# 4443	# 4350	# 3526
Total Assets (TTM) in million	67	79	89	102	120
Seq. Total Assets Change	-15.21 %	-11.75 %	-12.14 %	-15.06 %	-55.62 %
Seq. Net Income Change	-	-	-	-	-

CMPI's 5 Years Annual ROA >> Back to CMPI Management Effectiveness >> Compare CMPI ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 147
Sector	# 954
Overall	# 5111

Return On Assets Statistics
High	Average	Low
-11.77 %	-49.24 %	-74.99 %
(Mar 31 2021)		(Mar 31 2022)

Financial Statements
Checkmate Pharmaceuticals Inc 's Assets	$ 67 million	CMPI's Balance sheet
Checkmate Pharmaceuticals Inc 's Income	$ -16 million	Quarterly CMPI's Income Statement
CMPI's Income by Division		See CMPI's Income by Division

Annual Return On Assets	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020	FY	FY	FY
Y / Y Total Assets Change	-40.76 %	-	-	-	-
Total Assets in million	79	133	0	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-61	-37	0	0	0
Annual Return On Assets	-77.89 %	-28.08 %	-	-	-

CMPI's 5 Years Annual ROA >> Back to CMPI Management Effectiveness >> Compare CMPI ROA to its Competitors

More Return On Assets Ratios
CMPI's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CMPI's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CMPI's Competitors
Subscribers only: Roa for Checkmate Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for CMPI's Customers

You may also want to know
CMPI's Roi	CMPI's Inventory Turnover Ratio	CMPI's Growth Rates	CMPI's Dividend Comparisons
	CMPI's Profitability Ratios	CMPI's Asset Turnover Ratio	CMPI's Dividend Growth
CMPI's Roe	CMPI's Valuation Ratios	CMPI's Financial Strength Ratios	CMPI's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2022, within Healthcare Sector

ROA

Date modified: 2026-10-07T00:41:47+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.